Antengene to Participate in Three Upcoming Investor Conferences in May/June
CICC Healthcare Industry Forum 2022: May 9th to 12th BTIG Virtual China Biotech Day: June 1st Citi's 3rd Pan-Asia Regional Investor Conference 2022: June 8th to June 10th SHANGHAI and HONG KONG, May 6, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and...
Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 6, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX:02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, is pleased to announce the appointment of Alexander A. Zukiwski, MD, to the Company's Scientific Advisory Board. Dr. Zukiwski joined CASI...
World Lupus Federation Global Survey of People Living with Lupus finds 87% Report at Least One Major Organ Affected by the Disease
Survey Findings Released in Advance of World Lupus Day on May 10 WASHINGTON, May 6, 2022 /PRNewswire/ -- In a recent international survey, the World Lupus Federation found that 87% of the survey respondents living with lupus reported that the disease has impacted one or more major organs or organ systems. Over...
Insilico Medicine expands synthetic lethality portfolio with the nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers
NEW YORK, May 6, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-designed molecules for the treatment of methylthioadenosine phosphorylase (MTAP)-deleted cancers. The MAT2A program is part of Insilico's growing portfolio of synthetic lethality assets...
Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers
NEW YORK, May 5, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-designed molecules for the treatment of methylthioadenosine phosphorylase (MTAP)-deleted cancers. The PCC is part of Insilico's growing portfolio of synthetic lethality assets in...
AHRA and United Imaging launch a new program to develop exceptional leaders.
Announcing AHRA's Transformative Leaders of Choice Program HOUSTON, May 5, 2022 /PRNewswire/ -- AHRA, The Association for Medical Imaging Management, the professional organization representing all levels of management in hospital imaging departments, freestanding imaging centers, and group practices, announced that it is launching a three-year ongoing education program sponsored by United Imaging, the global medical imaging company with U.S....
HOYA Vision Care Releases Results of First of its Kind Six-Year MiYOSMART Spectacle Lens Follow-up Clinical Study
Strong evidence shows continued long-term lens effectiveness in slowing myopia progression in children BANGKOK, May 5, 2022 /PRNewswire/ -- HOYA Vision Care, a leader in optical technology innovation, shared the results of a six-year follow-up clinical study on its award winning MiYOSMART spectacle lens with Defocus Incorporated Multiple Segments (D.I.M.S.) Technology at the Association for Research in Vision and Ophthalmology...
The Future Investment Initiative Institute announces its regional summit titled Inclusive ESG for Emerging Markets
At the summit, FII institute will present a proprietary new inclusive ESG framework and scoring methodology developed for informing and accelerating ESG investments in emerging economies. RIYADH, Saudi Arabia, May 5, 2022 /PRNewswire/ -- The Future Investment Initiative (FII) Institute is hosting a summit, ESG in Emerging Markets, at Rosewood...
Bon Natural Life Limited Advances Towards Near Term Production and Completes Building Construction of Yumen Plant
HIGHLIGHTS OF A TRANSFORMATIVE 2022 Yumen Plant commissioning is on schedule and forecasted to commence around September 2022 to deliver near term production of fragrance compounds and bioactive food ingredients. A 200% increase in production capacity in these two product categories with 150% overall revenue growth potential on an annualized basis. Subsequent to the removal of VIE structure,...
Daewoong Pharmaceutical announced first-quarter 2022 results
- Marked sales of KRW 272.2 billion and operating profit of KRW 26.8 billion - Reported record-high quarterly operating profit, thanks to highly profitable ETC drugs and export growth of Nabota - Expected to see increasing profitability and robust growth due to export expansion of Nabota and the upcoming release of Fexuclue...
